Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation

被引:2
|
作者
Abay, Merve [1 ]
Ozgen, Levent [1 ]
Yalcin, Yakup [1 ]
Ozerkan, Kemal [1 ]
机构
[1] Uludag Univ, Fac Med, Gynecol Oncol Surg, TR-16059 Bursa, Turkiye
关键词
BRCA; 1/2; Ovarian carcinoma; Serous tubal intraepithelial carcinoma; Risk reducing salpingo-oophorectomy; FOLLOW-UP; CANCER; CARRIERS; OVARIAN; OUTCOMES; SURGERY;
D O I
10.1016/j.jogoh.2023.102642
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Serous tubal intraepithelial carcinoma (STIC) is a precursor lesion which is located in the distal fallopian tube and causes high grade serous ovarian carcinoma (HGSOC). The incidence of STIC for women underwent risk reducing salpingo-oophorectomy for BRCA mutation varies from 0.6 to 7% and its clinical outcomes are still unclear. The aim of this study was to demonstrate the incidence of STIC and HGSOC in BRCA1/2 mutation carriers after risk reducing salpingo-oophorectomy (RRSO) and the clinical outcomes of these patients. Material and methods: We retrospectively reviewed the records of 48 BRCA1 and/or 2 mutation carriers who underwent prophylactic salpingo-oophorectomy with or without hysterectomy at the Department of Obstetrics and Gynecology, Bursa Uludag University between January 2000 and January 2022. Inclusion criteria: BRCA 1 and/or 2 mutation carriers diagnosed by genetic testing, asymptomatic patients with no abnormal findings on pelvic examination. Exclusion criteria: patients with no abnormal findings on pelvic examination and a presence of a personal history of ovarian, fallopian tube or peritoneal cancer. Results: A total of 48 BRCA 1 and/or 2 mutation carriers underwent RRSO. STIC was diagnosed in 1 (2,0%) patient and restaging surgery was not performed. Primary peritoneal carcinoma (PPC) did not develop during the 20 months follow-up period. One (2.0%) patient was diagnosed with occult ovarian cancer. Restaging surgery was performed and chemotherapy treatments were given after surgery. A pelvic recurrence developed 25 months after the occult cancer diagnosis in the follow up period. One (2.0%) patient with normal histopathological findings after RRSO was diagnosed with peritoneal cancer 57 months after the operation. Conclusion: The risk of PPC continues after RRSO. Therefore, close follow-up procedure is very important for early diagnosis and effective treatment of patients with PPC after RRSO.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Stopping ovarian cancer screening in BRCA1/2 mutation carriers: Effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens
    van Driel, Catheleine M. G.
    de Bock, Geertruida H.
    Arts, Henriette J. G.
    Sie, Aisha S.
    Hollema, Harry
    Oostervvijk, Jan C.
    Mourits, Marian J. E.
    MATURITAS, 2015, 80 (03) : 318 - 322
  • [42] Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study
    Perri, Tamar
    Levin, Gabriel
    Naor-Revel, Shani
    Eliassi-Revivo, Perry
    Lifshitz, Dror
    Friedman, Eitan
    Korach, Jacob
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2022, 157 (02) : 431 - 436
  • [43] Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women
    Sidon, L.
    Ingham, S.
    Clancy, T.
    Clayton, R.
    Clarke, A.
    Jones, E. A.
    Lalloo, F.
    Evans, D. G. R.
    BRITISH JOURNAL OF CANCER, 2012, 106 (04) : 775 - 779
  • [44] Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations
    Solsky, Ian
    Chen, Jinbo
    Rebbeck, Timothy R.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (02) : 363 - 376
  • [45] Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know
    De Felice, F.
    Marchetti, C.
    Boccia, S. M.
    Romito, A.
    Sassu, C. M.
    Porpora, M. G.
    Muzii, L.
    Tombolini, V.
    Panici, P. Benedetti
    CANCER TREATMENT REVIEWS, 2017, 61 : 1 - 5
  • [46] Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation
    Dongwon Kim
    Eunyoung Kang
    Euijun Hwang
    Young Sun
    Yoonsun Hwang
    Cha Kyong Yom
    Kidong Kim
    Jae Hong No
    Yong-Beom Kim
    Sung-Won Kim
    Familial Cancer, 2013, 12 : 621 - 628
  • [47] Risk-reducing bilateral salpingo-oophorectomy: For whom, how and what results?
    Favier, Amelia
    Evrevin, Clemence
    Desseignes, Camille
    Benusiglio, Patrick R.
    Uzan, Catherine
    BULLETIN DU CANCER, 2025, 112 (03) : 307 - 315
  • [48] Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer
    Straub, Melissa M.
    Podoll, Mirna B.
    David, Stephanie N.
    Wiesner, Georgia L.
    Desouki, Mohamed M.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2018, 36 : 28 - 30
  • [49] Needleoscopic-assisted risk-reducing bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers: Peri-operative outcomes and psychological impact
    Andrea, Rosati
    Camilla, Fedele
    Anna, Fagotti
    Letizia, Lafuenti
    Alessandro, Gioe
    Rosaria, Chieffo Daniela Pia
    Giuseppe, Vizzielli
    Giovanni, D'Ippolito
    Vanda, Salutari
    Ida, Paris
    Claudia, Marchetti
    Giovanni, Scambia
    Salvatore, Gueli Alletti
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2022, 273 : 1 - 6
  • [50] The needs of Southeast Asian BRCA mutation carriers considering risk-reducing salpingo-oophorectomy: a qualitative study
    Hamizah Sa’at
    Yew-Kong Lee
    Sook-Yee Yoon
    Siu Wan Wong
    Yin Ling Woo
    Kristine Barlow-Stewart
    Nur Aishah Mohd Taib
    Familial Cancer, 2022, 21 : 21 - 33